Reagents and instruments for immunology, cell biology and molecular biology.
 
> MrgprX2 antagonist-1 [2642162-06-7]

MrgprX2 antagonist-1 [2642162-06-7]

Print Print
Please log in

Cat# HY-145191-5mg

Size : 5mg

Brand : MedChemExpress


Description

MrgprX2 antagonist-1 is an MrgprX2 antagonist extracted from patent WO2021092264A1, example E23. MrgprX2 antagonist-1 can be used for the research of inflammatory disorders of the skin[1].

IC50 & Target

MrgprX2[1]
In Vitro

MRGPRX2, a member of the Mas-related gene family, was found to be expressed in sensory neurons, mast cells and, most recently, in keratinocytes. MRGPRX2 mRNA is present in adipose tissue, esophagus, urinary bladder, lungs with the highest levels found in skin. Activation of MRGPRX2 leads to mast cell degranulation with subsequent pseudo-allergic reactions[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MrgprX2 antagonist-1 Related Antibodies

Solvent & Solubility
In Vitro: 

DMSO : 66.67 mg/mL (162.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.4369 mL 12.1844 mL 24.3688 mL
5 mM 0.4874 mL 2.4369 mL 4.8738 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (6.09 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (6.09 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Purity & Documentation
References

You might also be interested by the following products:



Cat#
Description
Cond.
Price Bef. VAT
HY-129047-100mg
Trypsin [9002-07-7]
 100mg 
HY-P3419-5mg
PAMP-12 (unmodified) [929905-12-4]
 5mg 
HY-P7057-50ug
TSLP, Human
 50ug